Jeffrey Freiberg, MD, PhD review of the SABATO trial on oral antibiotics for S aureus bacteremia and a comparison of mupirocin and iodine treatments for MRSA decolonization.
Although the pandemic halted many medical mission assignments, these opportunities and others are becoming available to help those geographic areas with acute needs.
For patients undergoing surgery, looking at the potential benefits of this antimicrobial for prophylaxis.
During these uncertain times, RAIN President and CEO Chelsea Gulden talks about the importance of taking a grassroots approach to HIV advocacy to work with young people in the local communities who are either dealing with the virus or are susceptible to it.
New meta-analysis at the 2025 vaccinology conference highlights the efficacy of maternal RSV vaccines, with calls for enhanced monitoring following safety issues with one candidate
Stacy Lindborg, PhD, highlights the vaccine’s immune response, safety, and global distribution potential.
Syra Madad, DHSC, MSc, MCP, CHEP, outlines early surveillance systems and diagnostic innovations for enhancing pandemic management and response.
This systematic review focuses on breakthrough invasive fungal infections (bIFIs) in patients with high-risk hematological cancers, like acute leukemia, or those who have undergone stem cell transplants. Despite prophylactic antifungal treatments (usually with voriconazole or posaconazole), bIFIs remain challenging due to their complexity and high mortality rates.
Investigators evaluated strategies to simplify the vaccination process to yield higher rates of adult immunization, similar to that of the COVID-19 pandemic.
Epidemiologic and clinical lessons for the uninitiated.
In this case study, clinicians review a challenging case.
Rifaquizinone is a dual-pharmacophore antibiotic combining rifamycin and a fluoroquinolone-like compound, showing strong bactericidal activity against resistant Staphylococcus aureus strains and biofilms, with promising results for treating prosthetic joint infections (PJI) but limited oral bioavailability.
Will there be an answer to keep the continuously evolving virus at bay? Are seasonal combination vaccines the wave of the future?
The pharmaceutical industry faces challenges when investing in new antibiotics, which emphasizes the need for regulatory reforms, incentives, and collaborative efforts between government, healthcare organizations, and private companies. The prospective bill, the Pasteur Act, is one potential strategy to help in these areas, and incentivize pharmaceutical companies to develop these essential therapies.
Extending antimicrobial stewardship programs to transition of care and discharge may prove beneficial to reduce unnecessary antibiotic use.
The antimicrobial resistance (AMR) crisis stems from natural microbial adaptation and the lack of new antimicrobials in development. Vulnerable populations worldwide, including within the US, are disproportionately affected, exacerbating the spread of resistance.
This week, Moderna’s mRNA-1010 flu vaccine showed strong phase 3 results, new research reveals that FMT may fail due to functional mismatches between donor microbes and the recipient’s gut, and more.
A review of the data and circumstances that led to authorization in children ages 5 to 11 years.
Conflicting priorities of infection control, antimicrobial stewardship, and critical care make the management of sepsis secondary to SARS-CoV-2 infection challenging.
Conflicting priorities of infection control, antimicrobial stewardship, and critical care make the management of sepsis secondary to SARS-CoV-2 infection challenging.
This bipartisan initiative highlights the need for a comprehensive approach to combat antimicrobial resistance (AMR), incorporating both antibiotic drug development and increased funding for stewardship programs.
Traditional therapy coverage does not include recent data that offers some updates in evaluating the current effectiveness of empiric antibiotic treatment.
How pharmacists can use shared decision-making to improve antibiotic use.
The latest Bench to Bedside column reviews new guidance on the treatment of drug-susceptible and drug-resistance Mycobacterium tuberculosis infections.
Experts provide practice pearls for educating patients on and using FMTs for the management of CDI.
Will there be an answer to keep the continuously evolving virus at bay? Are seasonal combination vaccines the wave of the future?
Four lessons learned from the AIDS crisis that can be applied to the fight against our current pandemic.
John Rex, MD, FACP, discusses the promise, precision, and challenges of this first-in-class antifungal following phase 2b trial results.
Scynexis developed its investigational fungal compound, SCY-247, which is in phase 1 clinical trials, and the company expects to share top-line data this year.